Vanguard Fiduciary Trust
CLDX icon

Vanguard Fiduciary Trust’s Celldex Therapeutics CLDX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6M Buy
552,973
+123,376
+29% +$3.99M ﹤0.01% 1405
2026
Q1 		$13.6M Buy
+429,597
New +$11.7M ﹤0.01% 1547

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's CLDX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Celldex Therapeutics (CLDX) stake by 29% in Q2 2026, buying an estimated $3.99M and bringing the position to 552,973 shares worth $20.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

Vanguard Fiduciary Trust first reported a position in CLDX in Q1 2026 and has held it in 2 quarters since. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Vanguard Fiduciary Trust held 552,973 shares of Celldex Therapeutics worth $20.6M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 123,376 Celldex Therapeutics shares in Q2 2026, an estimated $3.99M.
  • Celldex Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1405 holding.
  • Vanguard Fiduciary Trust first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.